Different Way | GenomeWeb

Different Way

The point of personalized medicine, as the mantra goes, is to bring the right treatment to the right patient at the right time. But getting such tailored therapies approved may mean that how clinical trials assessing their efficacy and safety are conducted needs to be re-thought, writes Susan Young at Technology Review.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

The Pair of Them

Mish Mash of Cells

Biopsy Troubles

Why So Few?

This Week in Science

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."